Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206063 · ClinicalTrials.gov registry record · Phase 2
Long Term Open Follow-up With H376/95 vs. Warfarin
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00206063 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 220 participants.
The verdict
NCT00206063, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
Interventions
- DRUG EXANTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 1999-08 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206063
The ClinicalTrials.gov registry entry for NCT00206063 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXANTA is the first listed.
NCT00206063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206063 about?
NCT00206063 is a clinical study titled "Long Term Open Follow-up With H376/95 vs. Warfarin". The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
What is the current status of trial NCT00206063?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 1999-08. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00206063?
The interventions under investigation include: EXANTA (DRUG).
Who is sponsoring clinical trial NCT00206063?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.